ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients
Conclusion: Immune assessment resulted in favorable anakinra responses among critically ill patients with COVID-19 and features of MALS.J Innate Immun
Source: Journal of Innate Immunity - Category: Allergy & Immunology Source Type: research
More News: Actemra | Allergy & Immunology | COVID-19 | Dexamethasone | Immunotherapy | Respiratory Medicine | SARS | Study